# Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.

> **NCT04877457** · PHASE4 · TERMINATED · sponsor: **Yale University** · enrollment: 3 (actual)

## Conditions studied

- Radiologically Isolated Syndrome
- Multiple Sclerosis

## Interventions

- **DRUG:** Ocrelizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04877457
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-15
- **Primary completion:** 2023-06-12
- **Final completion:** 2023-06-12
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Slow enrollment
- **Last updated:** 2024-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04877457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04877457, "Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04877457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*